乙種藜蘆鹼 | 124-80-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 乙種藜蘆鹼
• 中文别名: 乙種藜蘆鹼；乙种藜芦碱
• 英文名称: sabadine
• 英文别名: [(1R,2S,6S,9S,10R,11S,12S,14R,15R,18S,19S,20S,23R,24S)-1,10,11,12,14,19-hexahydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacosan-20-yl] acetate
• CAS: 124-80-1
• 化学式: C₂₉H₄₇NO₈
• 分子量: 537.694
• InChiKey: IJZIXCZIZHENJV-ONCBQHFTSA-N

物化性质

• 熔点：
  256-258° (dec)
• 比旋光度：
  D25 -11° (c = 1.93 in alc)
• 沸点：
  614.28°C (rough estimate)
• 密度：
  1.1622 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  38
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  151
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• [EN] SUBCUTANEOUS ADMINISTRATION OF A P2Y12 RECEPTOR ANTAGONIST<br/>[FR] ADMINISTRATION SOUS-CUTANÉE D'UN ANTAGONISTE DU RÉCEPTEUR P2Y12
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018167139A1

  公开（公告）日：2018-09-20

  The present invention relates to a P2Y12 receptor antagonist selected from the group consisting of4-((R)-2-[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, (1S,2S,3R,5S)-3- [7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, and (1S,2R,3S,4R)-4-[7- [(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2,3-triol, or a pharmaceutically acceptable salt thereof, for use as a medicament by subcutaneous or intradermal administration.

  本发明涉及一种P2Y12受体拮抗剂，所述拮抗剂选自以下组合物：4-((R)-2-[6-((S)-3-甲氧基吡咯烷-1-基)-2-苯基嘧啶-4-羰基]-氨基}-3-磷酸基丙酰基)-哌嗪-1-羧酸丁酯，(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-二氟苯基)环丙基氨基]-5-(丙基硫基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]-5-(2-羟乙氧基)环戊烷-1,2-二醇，以及(1S,2R,3S,4R)-4-[7-[(1R,2S)-2-(3,4-二氟苯基)环丙基氨基]-5-(丙基硫基)-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基]环戊烷-1,2,3-三醇，或其药学上可接受的盐，用于皮下或皮内给药的药物。
• Treatment of viral infections by modulation of host cell metabolic pathways
  申请人：Munger Josh

  公开号：US20090239830A1

  公开（公告）日：2009-09-24

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

  描述了在病毒感染时发生的某些代谢物浓度和通量的改变。选择涉及代谢途径的宿主细胞酶作为干预靶点；即恢复代谢通量以不利于病毒复制，或进一步扰乱代谢通量导致病毒感染细胞的“自杀”（但不包括未感染的细胞），以限制病毒传播。虽然可以选择相关代谢途径中的任何酶，但是在这些代谢途径中关键控制点的关键酶更适合作为候选抗病毒药物靶点。使用这些酶的抑制剂来逆转或重定向病毒感染的影响。使用体外筛选分析和宿主细胞以及动物模型测试药物候选物的抗病毒活性。然后使用动物模型测试候选化合物在预防和治疗病毒感染方面的功效。证明了酶抑制剂的抗病毒活性。
• TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS
  申请人：MUNGER Josh

  公开号：US20130065850A1

  公开（公告）日：2013-03-14

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

  描述了某些代谢物浓度和通量的改变，这些改变是对病毒感染的反应。选择参与代谢途径的宿主细胞酶作为干预的目标，即恢复代谢通量以削弱病毒复制，或进一步扰乱代谢通量导致病毒感染细胞的“自杀”（但不包括未感染的细胞），以限制病毒传播。虽然可以选择相关代谢途径中的任何酶，但是在这些代谢途径的关键控制点上的关键酶被优先选择作为候选抗病毒药物靶点。使用这些酶的抑制剂来扭转或重定向病毒感染的影响。通过体外和宿主细胞的筛选试验以及动物模型来测试药物候选物的抗病毒活性。然后使用动物模型来测试候选化合物在预防和治疗病毒感染方面的功效。证明了酶抑制剂的抗病毒活性。
• Oral rinse compositions
  申请人：VIPONT PHARMACEUTICAL, INC.

  公开号：EP0396232A2

  公开（公告）日：1990-11-07

  Mouthrinses containing sanguinarine of superior efficacy and increased uptake into dental plaque are attained by the development of stable mouthrinses adjusted to a pH in the range of 4.0 to 5.6, preferably about 4.5. Compositions may contain a zinc salt as an optional ingredient. Various types of buffer systems are described.

  将稳定的漱口水的 pH 值调整到 4.0 至 5.6 之间，最好在 4.5 左右，就能获得含有桑吉那林的漱口水，这种漱口水具有卓越的功效，并能提高牙菌斑的吸收率。组合物可含有锌盐作为可选成分。本文介绍了各种类型的缓冲体系。
• The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
  申请人：F. Hoffmann-la Roche AG

  公开号：EP1816477A1

  公开（公告）日：2007-08-08

  The present invention relates to a method for determining a risk whether an individual will suffer from a cardiovascular adverse event as a consequence of cardiac stress testing, comprising the steps of (a) measuring, preferably in vitro, the level of Placenta Growth Factor, wherein (b) if the level of the Placenta Growth Factor is at least increased, then the individual is at least at risk of suffering from an adverse event as a consequence of cardiac stress testing. In a further embodiment, additionally another marker is measured, particularly a natriuretic peptide, most particularly NT-proBNP. The present invention allows to stratify patients according to the environment and conditions under which cardiac stress testing should be carried out.

  本发明涉及一种确定个体是否会因心脏负荷试验而遭受心血管不良事件风险的方法，包括以下步骤：(a) 测量（最好是体外测量）胎盘生长因子的水平，其中(b) 如果胎盘生长因子的水平至少升高，则该个体至少有因心脏负荷试验而遭受不良事件的风险。在另一个实施方案中，还要测量另一种标记物，特别是利钠肽，尤其是 NT-proBNP。本发明可根据进行心脏负荷试验的环境和条件对患者进行分层。